imatinib / Generic mfg. - LARVOL DELTA

Imatinib in chronic myeloid leukemia: A comparative assessment of patients in pivotal clinical trials and real-world settings (ASH 2025) - " We included the imatinib arm of 5 pivotal CTs: the IRIS, which established the superiority of imatinib over interferon alfa plus cytarabine, and the DASISION, ENESTnd, BFORE, and ASC4FIRST trials, which supported the approvals of dasatinib, nilotinib, bosutinib, and asciminib, respectively. Patients in the RWD cohort exhibited higher clinical risk profiles, greater racial and ethnic diversity, and longer intervals between diagnosis and treatment initiation. These factors may contribute to the lower rates of achieving optimal treatment responses, including cytogenetic and molecular milestones. Despite these differences, long-term outcomes were comparable, aligning with current trends showing that survival in CML patients now approaches that of the general population."

Clinical • Real-world • Real-world evidence • Chronic Myeloid Leukemia • Hematological Malignancies • Leukemia • ABL1

Timing of tyrosine kinase inhibitor switching and long-term outcomes in chronic myeloid leukemia: A real-world comparative study (ASH 2025) - "This study evaluates the comparative safety and effectiveness of early switching (<3 months), late switching (≥6 months), and continued first-line TKI therapy across imatinib, dasatinib, and nilotinib. Switch timing in CML has substantial prognostic implications. Early TKI switching, especially within the first 3 months, is associated with higher mortality and complications. Late switching may be better tolerated, particularly with second-generation agents."

Clinical • Real-world • Real-world evidence • Chronic Myeloid Leukemia • Congestive Heart Failure • Diabetes • Heart Failure • Hematological Malignancies • Leukemia • Metabolic Disorders

Inhibitors of RAD51 as potential novel therapies in Acute Myeloid Leukemia (ASH 2025) - "Furthermore, these compounds often exhibit strong synergy and at least additivity in combination with both on-label and off-label use of FDA-approved compounds, as well as investigational molecularly-targeted agents, in relevant cell lines; these include FLT3 inhibitors quizartinib, gilteritinib and tuspetinib ((in MV-4-11 and HL60 cell lines) and BCR/ABL inhibitors (imatinib and regorafenib) in the K562 cell line (AACR 2025)...We have confirmed the IBRs inhibit multiple RAD51 functions including hydroxyurea-induced RAD51 focus formation, HRR by DR-GFP assay, and RS protection by RPA focus formation and a DNA fibre assay...JKYN-1 is a partially optimized (more soluble and more potent) version of IBR120 but is not resistant to degradation by liver microsomes or sufficiently capable of entry into target cells...Treatment dose and combinations will be pre-screened using a highly predictive cell line as a surrogate of human cancer stem cells for subsequently AML patient..."

Acute Myelogenous Leukemia • Colorectal Cancer • Hematological Malignancies • Leukemia • Solid Tumor • BRCA1 • BRCA2 • FLT3 • HRD • RAD51

Myeloid/lymphoid neoplasms with eosinophilia and tyrosine kinase gene fusions: A multi-center study in China (ASH 2025) - "In MLN with PDGFRA fusion genes, 22 patients in chronic phase(CP) were treated with imatinib, 1 patient with AML received chemotherapy + imatinib, and 1 patient with ALL received dasatinib + chemotherapy. The clinical manifestations of MLN-TK are different, which may involve multiple organs. The increase of eosinophils is more common, and the prognosis of BP or secondary BP seems to be worse."

Clinical • Bone Marrow Transplantation • Eosinophilia • Hematological Malignancies • Leukemia • Lymphoblastic Lymphoma • Lymphoma • Plasma Cell Leukemia • Sarcoma • Solid Tumor • ABL1 • ALK • ETV6 • FGFR1 • FLT3 • JAK2 • PDGFRA • PDGFRB • RANBP2 • RUNX1 • ZMYM2

The molecular landscape of patients with malignant histiocytosis (ASH 2025) - "Responders received a range of agents matched to their mutations: trametinib ( BRAFV600E, MAP2K1F53I, KRASQ16H/PTEND24G/EPHB1R327C, MAP2K1F53I/BCL2/CDKN1B/KIT, and CALR), dabrafenib + trametinib( BRAFG596R/KRASQ61H) , imatinib ( MAP2K1C121S/METG28881T/DUSP2G137D/HIST1H3BC97Y/GRIN2AS1216C and PTPN11/STK11/GNA11/JAK2) , chidamide + sintilimab( IDH2G515A/RHOAG50T/TET23344delC), sirolimus( PTEN/FGFR3/SETD2) and sorafenib ( BRAFD594G/KRASK117N/TP53). Despite this complexity, durable clinical responses to targeted agents are achievable, even in heavily mutated cases. These findings support the use of comprehensive genomic profiling in MH to identify therapeutic targets and guide precision treatment strategies."

Clinical • IO biomarker • Sarcoma • Solid Tumor • ADGRG6 • BCL2 • BCL6 • BRAF • CALR • CDK1 • CDKN1A • CDKN1B • CDKN2A • CDKN2B • CREBBP • CYTOR • DNMT3A • EGFR • FGFR3 • GNA11 • JAK2 • KRAS • MAP2K1 • NF1 • NRAS • NRF1 • PTEN • PTPN11 • SETD2 • STK11 • TET2 • TP53

Successful first-line use of pemigatinib in myeloid/lymphoid neoplasm with FGFR1 rearrangement: Clinical insights (ASH 2025) - "Although the disease usually follows an aggressive course with poor response to conventional chemotherapy or tyrosine kinase inhibitors (TKIs), such as imatinib, and allogeneic stem cell transplantation (allo-SCT) is required for long-term disease control, the development of targeted FGFR inhibitors has revolutionized treatment options. It also highlights the importance of early molecular diagnosis to enable timely and targeted treatment in these aggressive neoplasms, which may lead to complete metabolic responses. Molecular response with RT-qPCR for FGFR1 would be the next goal in the management of patients with MLN FGFR1 ."

Clinical • Alopecia • Dermatology • Dry Eye Disease • Dyslipidemia • Eosinophilia • Hematological Malignancies • Immunology • Leukemia • Lymphoma • Metabolic Disorders • Myeloproliferative Neoplasm • Nephrology • Ophthalmology • Renal Disease • Retinal Disorders • ABL1 • BCR • FGFR1 • JAK2 • ZMYM2

Systemic mastocytosis with associated lymphoid neoplasms (SM-ALN): A distinct subset with indolent clinical course and favorable outcomes (ASH 2025) - "SM management was divided into two categories: (1) Conservative approach, including observation alone in 4 patients (22%) and symptomatic therapies such as antihistamines or leukotriene inhibitors in 7 (39%); and (2) Cytoreductive treatments, comprising avapritinib in 5 patients (28%), cladribine in 1 (6%), and imatinib in 1 (6%). Management of lymphoid neoplasms included intensive regimens such as R-CHOP and hyper-CVAD for high-grade subtypes (e.g., DLBCL and T-ALL), while indolent forms (e.g., CLL and follicular lymphoma) were treated with bendamustine-rituximab or observation depending on disease burden... SM-ALN is a rare but distinct SM subtype characterized by indolent behavior, favorable treatment responses, and prolonged survival. Recognition of this subset is critical to avoid over-treatment and to guide risk-adapted management strategies."

Clinical • Acute Lymphocytic Leukemia • Aggressive Systemic Mastocytosis • B Cell Lymphoma • Chronic Lymphocytic Leukemia • Dermatology • Diffuse Large B Cell Lymphoma • Follicular Lymphoma • Hematological Malignancies • Hodgkin Lymphoma • Indolent Lymphoma • Leukemia • Lymphoma • Non-Hodgkin’s Lymphoma • Pruritus • T Acute Lymphoblastic Leukemia • T-cell Acute Lymphoblastic Lymphoma • ASXL1 • CCND3 • CXCR4 • DNMT3A • IDH1 • JAK2 • KIT • MYD88 • NOTCH2 • RUNX1 • SF3B1 • SRSF2 • TET2 • TP53

Asciminib as initial therapy with addition of lower dose tyrosine kinase inhibitors (TKIs) for patients with chronic myeloid leukemia who do not achieve optimal response or a deep molecular remission (ASH 2025) - P2 | "Patients who did not achieve MR4.5 after 24 months on asciminib, experienced treatment failure at any time or had a warning response at 12 months were offered the addition of lowTKI (imatinib 300 mg, dasatinib 50 mg or nilotinib 300 mg daily). Asciminib monotherapy demonstrated rapid early and deep molecular responses in patients with CP-CML, with a favorable safety profile. Further data will be presented for patients who added lowTKI."

Clinical • Chronic Myeloid Leukemia • CNS Disorders • Dermatology • Hypertension • Insomnia • Musculoskeletal Pain • Neutropenia • Pancreatitis • Sleep Disorder • Thrombocytopenia • ABL1

A case of delayed transformation to lymphoid blast crisis in a patient with chronic myeloid leukemia (ASH 2025) - "She was transitioned to nilotinib, followed by dasatinib due to cardiac side effects...Although this patient experienced resistance to imatinib early in her course and required three different TKI therapies, she had a major molecular response on dasatinib for over 10 years...Furthermore, the rate of transformation from CML to ALL is much less frequent than transformation from CML to AML, with the risk of transformation dramatically declining after 5 years of starting TKI therapy. This case highlights how a rare CML patient with an MMR may still go on to blast phase disease."

Clinical • Acute Lymphocytic Leukemia • Acute Myelogenous Leukemia • B Acute Lymphoblastic Leukemia • Chronic Myeloid Leukemia • Hematological Malignancies • Leukemia • ABL1 • BCR • CD20 • CD34 • CD79A • MME

Leonurine significantly enhance the activity of dendritic cells derived from chronic myeloid Leukemia Patients (ASH 2025) - "Compared with healthy donors, CML patients after imatinib therapy show no significant difference on the activity / maturation of moDCs. Leonurine significantly enhances the activity / maturation of CML patients derived moDCs, which is potential to be applied as a DC adjuvant in DC-based immunotherapy for CML patients."

Clinical • IO biomarker • Chronic Myeloid Leukemia • Hematological Malignancies • Leukemia • CD40 • CD83 • IL6

Chronic myeloid leukemia and ASXL1 mutations: A distinct entity requiring special attention (ASH 2025) - "Initial treatment: nilotinib 800 mg/day, reduced to 200 mg BID due to hematologic toxicity...Started 7+3 (cytarabine + daunorubicin) + ponatinib on 05/20/2025...NGS:WT1 p.C29_L30insCRHPGPEPRSVC* VAF 1.39%, ASXL1 p.G645Vfs*58 VAF 1.55%, ASXL1 p.E929G VAF 1.46% ,ASXL1 p.T936= VAF 1.41%(Tier 1) Started R-HyperCVAD + dasatinib...In the current era of CML targeted therapy with TKIs or myristoyl inhibitors, the presence of associated genetic alterations (AGAs) becomes relevant, as they may predict aggressive behavior and open a window to evaluate transplantation in these patients for better therapeutic responses. Imatinib is not benefical in this patients."

Chronic Myeloid Leukemia • CNS Disorders • Hematological Disorders • Hematological Malignancies • Hepatology • Herpes Zoster • Infectious Disease • Leukemia • Liver Failure • Musculoskeletal Pain • Myeloproliferative Neoplasm • Respiratory Diseases • Varicella Zoster • ABL1 • ASXL1 • CD20 • CEBPA • GATA2 • WT1

Impact of tyrosine kinase inhibitors on estimated glomerular filtration rate in chronic myeloid leukemia patients (ASH 2025) - "Conclusion Renal function remained stable in most CML patients on TKIs. However, dasatinib was associated with a significant eGFR decline, whereas imatinib and nilotinib showed no such effect."

Clinical • Acute Kidney Injury • Chronic Kidney Disease • Chronic Myeloid Leukemia • Hematological Malignancies • Leukemia • Nephrology • Renal Disease

Treatment-free remission in patients with chronic myeloid leukemia following the second discontinuation of tyrosine kinase inhibitors (ASH 2025) - "Treatment before first discontinuation was imatinib in 58.9% (n=23), nilotinib in 30.8% (n=12), and dasatinib in 10.3% (n=4). All 39 patients were alive at the final follow-up. Conclusion These results demonstrate that a second TKI stop is feasible and the majority of patients regain DMR within 6 months."

Clinical • Chronic Myeloid Leukemia • Hematological Malignancies • Leukemia • TFRC

Chemotherapy free ponatinib + asciminib achieves optimal disease controlpreallohsct in advanced – CML (ASH 2025) - "Pt1: Male, CML diagnosed at age 21; prior TKIs: imatinib, dasatinib, bosutinib; progressed to CML-BC at age 26; no response to ponatinib in monotherapy after two months so asciminib was added for 1 months of combination therapy. The distinct yet complementary mechanisms of TKIs were well tolerated in pt 1 and 2; its use in patients older than 50 years could require caution moreover if precedently treated with nilotinib. These preliminary results warrant further confirmation in larger prospective trials."

Metastases • Chronic Myeloid Leukemia • Myocardial Infarction • ABL1

Chronic myeloid leukaemia in the pregnancy: Experience at a university hospital in Paraguay (ASH 2025) - "Nineteen cases of unplanned pregnancies were recorded while receiving TKIs: fifteen on imatinib and four on dasatinib. Management strould be more aggressive. The duration of prior TKI exposure and exposure during pregnancy may be the most determining factors for a successful delivery"

Clinical • Chronic Myeloid Leukemia • Hematological Malignancies • Leukemia • ABL1

First report of real-word outcomes of chronic myeloid leukemia in Uruguay in tyrosine kinase inhibitor era (ASH 2025) - "No patient received nilotinib or bosutinib in 1L...Imatinib had the highest frequency of events (39.7%, mostly GI), followed by dasatinib (29.3%, mostly pleural effusion), and nilotinib (16.5%, mostly thrombocytopenia)...Although the disease follow-up could be biased, imatinib outcomes as 1L treatment was inferior to international reports, which suggest it can be improved with second generation TKI use in 1L, but cost and access could be an issue. OS are acceptable and similar to other reports, with significant differences according to known factors such as age, phase and risk."

Chronic Myeloid Leukemia • Hematological Disorders • Hematological Malignancies • Infectious Disease • Leukemia • Respiratory Diseases • Solid Tumor • Thrombocytopenia

Efficacy and safety of pegylated interferon alfa-2b combined with tyrosine kinase inhibitors in chronic Phase chronic myeloid leukemia patients with TKI resistance or intolerance (ASH 2025) - "Median follow-up was 72 weeks (range 24-96).Prior TKIs included imatinib, nilotinib, dasatinib, flumatinib,and olverembatinib.By June 30,2025.Sixteen, fourteen, ten, and eight patients completed therapy at weeks 24,48,72,and 96,respectively.Nine patients discontinued treatment due to adverse events.Molecular responses:Week 24: MMR 37.5% (6/16),DMR 6.3%(1/16),Week 48:MMR57.1% (8/14); Week 72: MMR40.0% (4/10); DMR 30.0% (3/10); Week 96: MMR 50.0% (4/8),DMR 25.0% (2/8).Safety:The most common AEs were flu-like symptoms and hematologic toxicities (predominantly grade 1-2).Dose reductions or extended dosing intervals (up to q2 weeks) of PEG IFNα-2b were implemented to manage AEs. Conclusion PEG IFNα-2b combined with TKIs significantly reduces BCR::ABL1 transcript levels, enabling patients with TKI-resistant or intolerant chronic-phase chronic myeloid leukemia (CP-CML) to achieve major molecular response (MMR) and even deep molecular response (DMR), with a favorable safety..."

Clinical • Chronic Myeloid Leukemia • Hematological Malignancies • Leukemia • ABL1 • IFNA1

Feasibility of the edmonton symptom assessment system (ESAS) score as patient-reported outcomes (PROs) assessment in chronic myeloid leukemia patients receiving tyrosine kinase inhibitor therapy: A pilot Study (ASH 2025) - "TKIs most frequently used before discontinuation were dasatinib (n=8 out of 27 pts, 30%), bosutinib (n=3/8, 37%), imatinib (n=3/5, 60%), nilotinib (n=2/6, 33%), and asciminib (n=2/27, 7%). Additionally, ESAS may be valuable for longitudinal follow-up to assess symptom evolution after treatment changes. Prospective studies with larger cohorts are warranted to validate these observations and determine whether symptom-guided strategies can improve TKI adherence and clinical outcomes in CML."

Clinical • Patient reported outcomes • Anorexia • Chronic Myeloid Leukemia • CNS Disorders • Depression • Hematological Malignancies • Leukemia • Mood Disorders • Palliative care

Treatment free remission after asciminib (ABL001) based therapy in chronic Phase chronic myeloid leukemia (CP-CML) patients who relapsed after a prior attempt at TKI discontinuation-h jean khoury cure CML consortium study HJKC3-0003 (ASH 2025) - "This trial will use any of the following (based on patient/physician preference) during the consolidation treatment phase: asciminib 40 mg PO daily plus imatinib (maximum dose of 400 mg PO once daily), asciminib 40 mg PO bid plus nilotinib (maximum dose of 300 mg bid), asciminib 80 mg PO daily plus dasatinib (maximum dose of 100 mg daily), asciminib 80 mg PO daily. This is the first report of asciminib use to attempt 2 nd TFR. The combination was well tolerated, and patients were able to complete the combination phase. Preliminary results suggest feasibility and potential to increase cure for CML."

Clinical • Chronic Myeloid Leukemia • Hematological Malignancies • Leukemia

Phase-3 study of vamotinib (PF-114) versus high-dose imatinib (ASH 2025) - "Conclusion Vamotinib, 300 mg, is as safe as imatinib, 800 mg, but more effective in achieving 1-year MMR. The study is ongoing."

P3 data • Chronic Myeloid Leukemia • Hematological Malignancies • Leukemia • ABL1

Mortality trends in chronic myeloid leukemia in the United States: A population-based analysis (ASH 2025) - "Discussion The substantial reduction in CML mortality over the past two decades aligns with the widespread adoption of TKIs, particularly imatinib (approved 2001). The subsequent approval of dasatinib (2006), nilotinib (2007), and bosutinib (2012) has aided in the transformation of CML from a fatal disease to a chronic condition for most patients...Males and White individuals face higher apparent mortality rates. The slight uptick in mortality from 2018 to 2020 may be related to the increased vulnerability of patients with hematologic malignancies to severe COVID-19 infection."

Clinical • Chronic Myeloid Leukemia • Hematological Malignancies • Infectious Disease • Leukemia • Novel Coronavirus Disease • ABL1 • BCR

Comparative 3- and 5-year outcomes among first-line imatinib, dasatinib, and nilotinib in chronic myeloid leukemia: A real world analysis (ASH 2025) - "Imatinib showed the most favorable survival at 3 and 5 years. Dasatinib was associated with higher mortality but lower diabetes risk, while nilotinib offered similar survival and a trend toward reduced hospitalizations. These results support personalized TKI selection in frontline CML therapy."

Clinical • Real-world • Real-world evidence • Chronic Myeloid Leukemia • Coronary Artery Disease • Diabetes • Hematological Malignancies • Hypertension • Leukemia • Metabolic Disorders

Dasatinib as 2nd line treatment is safe and effective in peruvian CML patients: A multicentric real-world study (ASH 2025) - "Background: The second-generation tyrosine kinase inhibitor Dasatinib (DAS) used as second-line treatment is a valid option in patients with CML after resistance or intolerance to prior Imatinib (IMA). In this Peruvian real-life cohort we found that DAS as second-line treatment in CML patients is a safe and effective therapy with high RMM rate, low rates of G3-4 pleural effusion and a discontinuation rate similar to other studies, with 57.1% of pts remaining on treatment at the last follow-up. This data will help take actions to improve the outcomes of Peruvian CML patients."

Clinical • Real-world • Real-world evidence • Chronic Myeloid Leukemia • Respiratory Diseases

DNA methylation instability as a biomarker to predict resistance or progression to advanced disease Phase following tyrosine kinase inhibitor therapy in chronic myeloid leukemia (ASH 2025) - "Most patients (n = 65, 84%) received imatinib as first-line therapy...Our findings contribute to improved patient risk and treatment stratification. Its correlation with BCR::ABL1 transcript level results warrants further refinement."

Biomarker • Epigenetic controller • Metastases • Chronic Myeloid Leukemia • Hematological Malignancies • Leukemia • ABL1

Overcoming asciminib resistance by targeting compound BCR::ABL1 mutations in chronic myeloid leukemia (ASH 2025) - "Selected candidate compounds demonstrating efficacy were validated across a panel of CML models, including Ba/F3 cells expressing wild-type BCR::ABL1, the T315I mutant (Ba/F3 T315I), and compound mutations (Ba/F3 PR: Y253H, E255K, and T315I), as well as K562 cells and their drug-resistant derivatives, K562 imatinib-resistant (K562 IR) and K562 ponatinib-resistant (K562 PR). CML cells with compound BCR::ABL1 mutations exhibited resistance to asciminib and, in part, to ponatinib, while bortezomib and selinexor retained efficacy in these resistant cells. Olverembatinib effectively suppressed proliferation and induced apoptosis in ABL TKI-resistant CML cells. The combination of olverembatinib and selinexor synergistically induced apoptosis and suppressed proliferation, offering a promising approach for overcoming TKI-resistant CML with compound mutations."

IO biomarker • Chronic Myeloid Leukemia • Hematological Malignancies • Leukemia • ABL1 • CASP3 • CASP7